Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
Mader
R M
RM
Department of Internal Medicine I, Division of Oncology, Vienna University School of Medicine, Vienna, Austria.
Schrolnberger
C
C
Rizovski
B
B
Brunner
M
M
Wenzel
C
C
Locker
G
G
Eichler
H G
HG
Mueller
M
M
Steger
G G
GG
D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019075:Electrophoresis, Capillary; D005110:Extracellular Space / Q000378:metabolism; D005467:Floxuridine / Q000378:metabolism; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D011355:Prodrugs / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000556:secondary; D014018:Tissue Distribution
D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D005467:Floxuridine; D003841:Deoxycytidine; D000069287:Capecitabine; C418208:5'-deoxy-5-fluorocytidine; D005472:Fluorouracil; C025034:doxifluridine